LY-CovMab

Luye Pharma Group Ltd. · Phase 1 active Small molecule

At a glance

Generic name	LY-CovMab
Sponsor	Luye Pharma Group Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY-CovMab CI brief — competitive landscape report
LY-CovMab updates RSS · CI watch RSS
Luye Pharma Group Ltd. portfolio CI